Study identifier:5077IL/0053
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicentre, Double-Blind Randomised Comparison of SEROQUELTM and Risperidone in the Treatment of Schizophrenic Patients with Acute Exacerbation (5077IL/0053)
schizophrenia
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|